Long term survival after brain metastases from malignant melanoma

Carmen Salvador-Coloma, Joaquín Montalar, Óscar Mauricio Niño, Alejandro Tormo, Jorge Aparicio


We present the case of a 32-year-old patient with malignant melanoma who relapsed with an unresectable brain metastases (BM). He was managed with whole brain radiotherapy (WBRT) and temozolomide chemotherapy. A metabolic positron emission tomography (PET-scan) complete response was achieved. He is living disease-free more than 6 years after the diagnosis of BM. He is now 51 years old and remains asymptomatic and free of disease since then. However, a pronounced residual image still appears on magnetic resonance imaging (MRI) ant PET-scan.


Malignant melanoma, Brain metastases, Long-term survival, Unresectable brain metastases

Full Text:



Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006;64:106-13.

Mahmood H, Faheem M, Asghar Hussain Asghar AH, et al. Long-Term Survivor of Brain Metastases from Malignant Melanoma. J Coll Physicians Surg Pak. 2010;20(12):832-4.

Hall WA, Djalilian HR, Nussbaum ES, et al. Long-term survival with metastatic cancer to the brain. Med Oncol. 2000;17(4):279-86.

Kotb S, Detappe A, Lux F, et al. Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial. Theranostics. 2016;6(3):418-27.

Shapiro DG and Samlowski W. Management of melanoma brain metastases in the era of targeted therapy. J Skin Cancer. 2011;2011:845863.

Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol. 1999;44(3):275-81.

Maher E, McKee A. Neoplasms of the central nervous system, in Atlas of Diagnostic Oncology. 3rd ed. Elsevier Science, London, UK, 2003.

Lee JY, Lunsford LD, Subach BR, et al. Brain surgery with image guidance: current recommendations based on a 20-year assessment. Stereotact Funct Neurosurg. 2000;75(1):35-48.

Solan MJ, Brady LW. Skin cancer. Principles and practice of radiation oncology. Philadelphia: Lippincott Williams & Wilkins; 2008.

Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293-300.

Bhatnagar A, Flickinger J, Kondziolka D, Lunsford L. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys. 2006;64(3):898–903.

Manon R, O’Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an eastern cooperative oncology group study (E 6397). J Clin Oncol. 2005;23(34):8870-6.

Meier S, Baumert BG, Maier T, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004;27:145-9.

Chiarion-Sileni V, Murr R, Pigozzo J, et al. Brain metastases from malignant melanoma. Forum (Genova). 2003;13(2):170-82.

Rao G, Klimo P, Thompson C, et al. Stereotactic radiosurgery as therapy for melanoma, renal carcinoma, and sarcoma brainmetastases: impact of added surgical resection and whole-brain radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(4):S20-5.

Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant wholebrain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebralmetastases: results of the EORTC 22952–26001 study. J Clin Oncol. 2011;29(2):134–41.

Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483–91.

Agarwala S, Kirkwood J, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22(11):2101–7.

Goldinger SM, Panje C, Nathan P. Treatment of melanoma brain metastases. Curr Opin Oncol. 2016;28(2):159-65.

DOI: http://dx.doi.org/10.14319/ijcto.44.8

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013